Results 41 to 50 of about 14,813,386 (261)
, 2023 reservedChimeric Antigens Receptor (CAR) T cells adoptive transfer represents a revolutionary strategy in cancer treatment. Indeed, anti-CD19 CAR T cells therapy has dramatically changed the fate of patients with relapsed/refractory (r/r)diffuse large ...
DARBAN, HANIEH
core
Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas
, 2022 CD19CAR T cells facilitate a transformational treatment in various relapsed and refractory aggressive B-lineage cancers. In general, encouraging response rates have been observed in B-lineage-derived non-Hodgkin’s lymphomas treated with CD19CAR T ...
Christian Martin Seitz +11 more
core +1 more source
CAR T Cell Therapy for Neuroblastoma [PDF]
Frontiers in Immunology, 2018 Patients with high risk neuroblastoma have a poor prognosis and survivors are often left with debilitating long term sequelae from treatment. Even after integration of anti-GD2 monoclonal antibody therapy into standard, upftont protocols, 5-year overall survival rates are only about 50%. The success of anti-GD2 therapy has proven that immunotherapy can
Rebecca M. Richards +2 more
openaire +3 more sources
, 2023 Tingyu Liang,* Yixuan Song,* Lingui Gu, Yu Wang, Wenbin Ma Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China*These ...
Liang T, Gu L, Wang Y, Song Y, Ma W
core
Low-Frequency PPM1D Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma [PDF]
, 2023 Chimeric antigen receptor T (CAR T)-cell therapy has become a standard treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Mutations in the PPM1D gene, a frequent driver alteration in clonal hematopoiesis (
Pabst, Thomas +13 more
core +2 more sources
Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data [PDF]
, 2020 Chimeric antigen receptor (CAR) T-cell therapy has shown promise in the treatment of haematological cancers and is currently being investigated for solid tumours, including high-grade glioma brain tumours.
Brown, Christine E. +15 more
core +2 more sources
Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
Biomarker Research, 2021 B-cell non-Hodgkin lymphoma (B-NHL) is a group of heterogeneous disease which remains incurable despite developments of standard chemotherapy regimens and new therapeutic agents in decades.
Zixun Yin, Ya Zhang, Xin Wang
doaj +1 more source
Generation of CAR-T cell lines
, 2023 Many forms of hematological malignancies as well as solid tumours can be treated using cellular immunotherapy, such as CAR-T, a treatment using T cells that express an antibody-based chimeric antigen receptor targeting tumor antigen.
Lima de Souza Pinto, Maria Eduarda
core
Organoids in pediatric cancer research
FEBS Letters, EarlyView.Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley +1 more source
CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
Frontiers in Immunology, 2023 Over the last decade, the survival outcome of patients with multiple myeloma (MM) has been substantially improved with the emergence of novel therapeutic agents, such as proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies ...
Xiaomin Zhang +4 more
doaj +1 more source